$Nektar Therapeutics (NKTR.US)$
This Phase 2 trial announcement represents a strategic advancement in Nektar's development of rezpegaldesleukin for type 1 diabetes treatment. The collaboration with TrialNet, a leading international diabetes research network, significantly enhances the trial's credibility and execution potential. The study's design is particularly robust, incorporating both mixed meal tolerance testing and C-peptide preservation measurements - important ma...

$Nektar Therapeutics (NKTR.US)$
Can This New Diabetes Treatment Change T1D Patient Care? Major Trial Announced

$Nektar Therapeutics (NKTR.US)$ 🚀🚀

smallest win! hahahahah. so stupid but fun.
$Nektar Therapeutics (NKTR.US)$

$Nektar Therapeutics (NKTR.US)$
taking a position here

$Nektar Therapeutics (NKTR.US)$
The FDA's Fast Track designation for rezpegaldesleukin marks a important inflection point for Nektar Therapeutics in the $14 billion global atopic dermatitis market. The designation's significance extends beyond mere regulatory acceleration - it validates the drug's novel approach in a highly competitive landscape dominated by JAK inhibitors and biologics like Dupixent.
The drug's mechanism of action targeting regulatory T c...

$Nektar Therapeutics (NKTR.US)$
Nektar's Breakthrough: FDA Accelerates Path for Revolutionary Skin Disease Treatment

$Nektar Therapeutics (NKTR.US)$ Reuters· 1 min ago
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Monday, 10th February at 7:00 am
SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-sever...

$Nektar Therapeutics (NKTR.US)$
The completion of target enrollment in REZOLVE-AD Phase 2b trial represents a significant milestone for Nektar's rezpegaldesleukin program. The 396-patient study achieved enrollment in just 14 months, indicating strong interest from both physicians and patients. The trial's design is particularly robust with its multi-regional approach spanning Europe (67%), US (17%), Canada (11%) and Australia (5%).
The study's focus on treatment-naïve p...